Oral idarubicin, dexamethasone and vincristine in the treatment of multiple myeloma: Final analysis of a phase II trial

Axel Glasmacher; Hartmut Goldschmidt; Jörg Mezger; Torsten Haferlach; Ingo G.H. Schmidt-Wolf; Frank Gieseler

Oral idarubicin, dexamethasone and vincristine in the treatment of multiple myeloma: Final analysis of a phase II trial

Axel Glasmacher^*, Hartmut Goldschmidt, Jörg Mezger, Torsten Haferlach, Ingo G.H. Schmidt-Wolf, Frank Gieseler

^*Korrespondierende/r Autor/-in für diese Arbeit

Medizinische Klinik I

3 Zitate (Scopus)

Abstract

This prospective phase II study evaluated a regimen with vincristine, oral idarubicin and dexamethasone (VID) in 74 patients with multiple myeloma. A partial response was achieved in 57% (16/28) of patients with previously untreated disease and in 35% (16/46) with refractory diseases. VID chemotherapy is an effective and tolerable oral alternative in an outpatient setting for these patients.

Originalsprache	Englisch
Zeitschrift	Haematologica
Jahrgang	89
Ausgabenummer	3
Seiten (von - bis)	371-373
Seitenumfang	3
ISSN	0390-6078
Publikationsstatus	Veröffentlicht - 03.2004

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

Weitere Links

Link to publication in Scopus

Zitieren

@article{2369d537a62e459aa3b8438d2d3ebc68,

title = "Oral idarubicin, dexamethasone and vincristine in the treatment of multiple myeloma: Final analysis of a phase II trial",

abstract = "This prospective phase II study evaluated a regimen with vincristine, oral idarubicin and dexamethasone (VID) in 74 patients with multiple myeloma. A partial response was achieved in 57% (16/28) of patients with previously untreated disease and in 35% (16/46) with refractory diseases. VID chemotherapy is an effective and tolerable oral alternative in an outpatient setting for these patients.",

author = "Axel Glasmacher and Hartmut Goldschmidt and J{\"o}rg Mezger and Torsten Haferlach and Schmidt-Wolf, {Ingo G.H.} and Frank Gieseler",

year = "2004",

month = mar,

language = "English",

volume = "89",

pages = "371--373",

journal = "Haematologica",

issn = "0390-6078",

number = "3",

}

TY - JOUR

T1 - Oral idarubicin, dexamethasone and vincristine in the treatment of multiple myeloma: Final analysis of a phase II trial

AU - Glasmacher, Axel

AU - Goldschmidt, Hartmut

AU - Mezger, Jörg

AU - Haferlach, Torsten

AU - Schmidt-Wolf, Ingo G.H.

AU - Gieseler, Frank

PY - 2004/3

Y1 - 2004/3

N2 - This prospective phase II study evaluated a regimen with vincristine, oral idarubicin and dexamethasone (VID) in 74 patients with multiple myeloma. A partial response was achieved in 57% (16/28) of patients with previously untreated disease and in 35% (16/46) with refractory diseases. VID chemotherapy is an effective and tolerable oral alternative in an outpatient setting for these patients.

AB - This prospective phase II study evaluated a regimen with vincristine, oral idarubicin and dexamethasone (VID) in 74 patients with multiple myeloma. A partial response was achieved in 57% (16/28) of patients with previously untreated disease and in 35% (16/46) with refractory diseases. VID chemotherapy is an effective and tolerable oral alternative in an outpatient setting for these patients.

UR - http://www.scopus.com/inward/record.url?scp=2942740800&partnerID=8YFLogxK

M3 - Journal articles

C2 - 15020285

AN - SCOPUS:2942740800

SN - 0390-6078

VL - 89

SP - 371

EP - 373

JO - Haematologica

JF - Haematologica

IS - 3

ER -

Oral idarubicin, dexamethasone and vincristine in the treatment of multiple myeloma: Final analysis of a phase II trial

Abstract

UN SDGs

Weitere Links

Fingerprint

Zitieren